

SUPPLEMENTAL FIGURE LEGENDS

Supplemental Fig. S1. Sequences, affinities, and specificities of antigen-binding Fabs from repertoire H3-SX. CDR sequences at positions that were randomized in the libraries are shown for Fabs selected for binding to (A) insulin, (B) IGF-1, (C) VEGF, and (D) HER2. The *fraction unbound* was determined as the ratio of the phage ELISA signal in the presence of 100 nM solution-phase antigen divided by the signal in the absence of solution-phase antigen; clones with less than 90% binding in the presence of the competing antigen are highlighted in bold font. IC₅₀ values were determined by competitive phage ELISA. Specificity ELISA signals are highlighted as follows: 1.0<dark grey; 0.2<light grey<1.0; 0.2>white; specificity signals >2 are in bold. Binding was assayed for the following antigens: human VEGF, HER2, human death receptor DR5 (hDR5), human insulin, neutravidin (NAV), human growth hormone (HGH), human insulin-like growth factor-1 (hIGF-1), and bovine serum albumin (BSA).

Supplemental Fig. S2. Sequences, affinities, and specificities of antigen-binding Fabs from repertoire All-SX. CDR sequences at positions that were randomized in the libraries are shown for Fabs selected for binding to (A) insulin, (B) IGF-1, (C) VEGF, and (D) HER2. The *fraction unbound* was determined as the ratio of the phage ELISA signal in the presence of 100 nM solution-phase antigen divided by the signal in the absence of solution-phase antigen; clones with less than 90% binding in the presence of the competing antigen are highlighted in bold font. IC₅₀ values were determined by competitive phage ELISA. Specificity ELISA signals are highlighted as follows: 1.0<dark grey; 0.2<light grey<1.0; 0.2>white; specificity signals >2 are in bold. Binding was assayed for the following antigens: human VEGF, HER2, human death receptor DR5 (hDR5), human insulin, neutravidin (NAV), human growth hormone (HGH), human insulin-like growth factor-1 (hIGF-1), and bovine serum albumin (BSA).

Supplemental Fig. S3. Sequences, affinities, and specificities of the heavy-chains of antigen-binding Fabs from repertoire H3-YX. The light-chain was not sequenced. CDR sequences at positions that were randomized in the libraries are shown for Fabs selected

for binding to (A) insulin, (B) IGF-1, (C) VEGF, and (D) HER2. The *fraction unbound* was determined as the ratio of the phage ELISA signal in the presence of 100 nM solution-phase antigen divided by the signal in the absence of solution-phase antigen; clones with less than 90% binding in the presence of the competing antigen are highlighted in bold font. IC₅₀ values were determined by competitive phage ELISA. Specificity ELISA signals are highlighted as follows: 1.0<dark grey; 0.2<light grey<1.0; 0.2>white; specificity signals >2 are in bold. Binding was assayed for the following antigens: human VEGF, HER2, human death receptor DR5 (hDR5), human insulin, neutravidin (NAV), human growth hormone (HGH), human insulin-like growth factor-1 (hIGF-1), and bovine serum albumin (BSA).

Supplemental Fig. S4. Sequences, affinities, and specificities of the heavy-chains of antigen-binding Fabs from repertoire All-YX. The light-chain was not sequenced. CDR sequences at positions that were randomized in the libraries are shown for Fabs selected for binding to (a) insulin, (b) IGF-1, (c) VEGF, and (d) HER2. The *fraction unbound* was determined as the ratio of the phage ELISA signal in the presence of 100 nM solution-phase antigen divided by the signal in the absence of solution-phase antigen; clones with less than 90% binding in the presence of the competing antigen are highlighted in bold font. IC₅₀ values were determined by competitive phage ELISA. Specificity ELISA signals are highlighted as follows: 1.0<dark grey; 0.2<light grey<1.0; 0.2>white; specificity signals >2 are in bold. Binding was assayed for the following antigens: human VEGF, HER2, human death receptor DR5 (hDR5), human insulin, neutravidin (NAV), human growth hormone (HGH), human insulin-like growth factor-1 (hIGF-1), and bovine serum albumin (BSA).

Supplemental Fig. S5. Sequences and affinities of antigen-binding Fabs from repertoire H3-YSGX. CDR sequences at positions that were randomized in the libraries are shown for Fabs selected for binding to (a) IGF-1, (b) insulin, (c) HER2, and (d) VEGF. The *fraction unbound* was determined as the ratio of the phage ELISA signal in the presence of 100 nM solution-phase antigen divided by the signal in the absence of solution-phase antigen. IC₅₀ values were determined by competitive phage ELISA.

Supplemental Figure S1a

Fab	CDR-L3			CDR-H1			CDR-H2			CDR-H3			Fraction unbound	Specificity ELISA signal Optical Density (450 nm)							
	hVEGF	HER2	hInsulin	NAV	HIGH	hIGF-1	BSA														
1	X	X	X	S	I	S	S	S	Y	Y	Y	Y	1.22	0.25	0.04	0.10	3.74	0.21	0.31	1.01	0.04
2	X	X	X	S	I	S	Y	S	S	Y	Y	Y	1.35	0.10	0.03	0.04	3.93	0.15	0.10	2.56	0.01
3	X	X	X	S	I	S	S	S	S	Y	Y	Y	1.28	0.08	0.01	0.01	4.02	0.11	0.09	1.64	-0.01
4	S	Y	S	Y	S	Y	S	S	S	W	W	S	0.58	0.14	0.03	0.02	3.74	0.10	0.07	0.18	0.00
5	X	X	X	S	I	S	S	S	S	S	S	S	0.93	1.64	0.18	0.83	3.60	0.63	1.95	5.87	0.16
6	X	X	X	S	I	S	S	S	S	S	S	S	0.87	2.82	0.45	2.26	4.07	1.74	3.25	3.32	0.57
7	Y	S	S	Y	S	Y	S	S	S	S	S	S	1.12	1.93	0.19	1.55	5.89	0.84	3.60	3.28	0.18
8	Y	S	S	Y	S	Y	S	S	S	S	S	S	0.82	1.61	0.18	1.07	3.70	0.72	2.05	3.21	0.18
9	Y	S	S	Y	S	Y	S	S	S	S	S	S	0.88	3.85	1.16	4.78	5.89	3.24	5.89	3.40	2.03
10	Y	S	S	Y	S	Y	S	S	S	S	S	S	0.96	0.50	0.07	0.37	5.89	0.22	0.60	1.14	0.01
11	Y	S	S	Y	S	Y	S	S	S	S	S	S	0.94	0.35	0.04	0.27	4.11	0.18	0.50	2.96	0.03
12	Y	S	S	Y	S	Y	S	S	S	S	S	S	1.08	0.54	0.07	0.54	3.88	0.30	0.70	3.10	0.08
13	Y	S	S	Y	S	Y	S	S	S	S	S	S	0.99	0.80	0.11	0.84	3.59	0.41	1.05	2.36	0.17
14	Y	S	S	Y	S	Y	S	S	S	S	S	S	1.12	1.77	0.26	1.84	3.95	1.06	2.61	3.47	0.44
15	Y	S	S	Y	S	Y	S	S	S	S	S	S	1.13	0.80	0.06	0.23	4.18	0.23	0.66	2.97	0.05
16	X	X	X	S	I	S	S	S	S	S	S	S	1.00	0.49	0.07	0.59	3.73	0.31	0.64	3.08	0.07
17	Y	S	S	Y	S	Y	S	S	S	S	S	S	0.76	2.37	0.30	2.43	3.60	1.18	3.26	3.43	0.31
18	Y	S	S	Y	S	Y	S	S	S	S	S	S	0.94	0.43	0.05	0.22	5.89	0.19	0.48	2.60	0.02
19	Y	S	S	Y	S	Y	S	S	S	S	S	S	0.94	1.35	0.13	0.80	3.67	0.54	2.10	3.55	0.07
20	Y	S	S	Y	S	Y	S	S	S	S	S	S	0.78	2.39	0.35	3.01	5.89	1.46	5.89	3.80	0.69
21	Y	S	S	Y	S	Y	S	S	S	S	S	S	0.83	0.64	0.11	0.58	3.61	0.35	0.86	1.48	0.11
22	Y	S	S	Y	S	Y	S	S	S	S	S	S	1.12	0.52	0.08	0.32	5.89	0.24	0.96	1.91	0.01
23	S	I	S	S	Y	S	S	S	S	S	S	S	0.87	0.40	0.20	0.61	3.13	0.36	0.81	0.60	0.07
24	Y	S	S	Y	S	Y	S	S	S	S	S	S	1.36	0.92	0.18	1.03	3.27	0.64	1.73	0.87	0.04
25	S	Y	S	S	Y	S	S	S	S	S	S	S	0.50	2.96	0.67	3.18	4.02	2.69	3.63	3.33	0.64
26	Y	S	S	Y	S	Y	S	S	S	S	S	S	0.96	2.77	0.51	2.55	5.89	2.33	3.77	2.14	0.35
27	Y	S	S	Y	S	Y	S	S	S	S	S	S	0.78	0.23	0.09	0.17	3.56	0.16	0.22	0.16	-0.04
28	S	S	Y	S	S	Y	S	S	S	S	S	S	1.02	0.97	0.14	1.52	3.97	0.62	1.96	2.02	0.05
29	S	S	Y	S	S	Y	S	S	S	S	S	S	1.06	1.63	0.29	1.94	5.89	1.31	3.10	1.38	0.11
30	S	Y	S	S	Y	S	S	S	S	S	S	S	1.69	1.52	0.24	2.19	4.15	1.12	3.14	2.03	0.11
31	Y	S	S	Y	S	Y	S	S	S	S	S	S	0.86	1.01	0.17	1.34	5.89	0.70	2.20	2.95	0.04
32	S	Y	S	S	Y	S	S	S	S	S	S	S	1.25	3.30	0.77	3.50	4.46	2.51	4.03	4.11	0.51
33	X	X	X	S	I	S	S	S	S	S	S	S	1.01	0.23	0.03	0.15	3.68	0.17	0.35	0.29	0.00
34	S	S	Y	S	S	Y	S	S	S	S	S	S	1.51	0.65	0.13	0.63	2.87	0.61	1.20	0.44	0.05

Supplemental Figure S2a

Fab	CDR-L3				CDR-H1				CDR-H2				CDR-H3				Fraction unbound	Specificity ELISA signal Optical density (450 nm)											
	19	20	21	22	28	29	30	31	52	53	54	55	95	96	97	98		100	101	102	103	hVEGF	HER2	hDR5	hInsulin	NAV	HGH	hIGF-1	BSA
1	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	S	Y	S	Y	S	Y	S	Y	0.86	0.24	0.07	0.13	5.89	0.17	0.30	0.39	0.05
2	W	W	S	S	W	W	S	W	T	S	S	S	S	S	W	W	S	S	W	W	1.12	0.74	0.20	0.45	3.87	1.01	1.76	4.40	0.36
3	W	W	S	S	W	W	S	W	T	S	S	S	S	S	W	W	S	S	W	W	1.05	0.72	0.20	0.36	5.89	0.84	1.33	2.94	0.27
4	S	W	S	W	S	S	W	S	S	W	S	W	S	W	S	W	S	W	S	W	1.09	0.26	0.06	0.15	5.89	0.38	0.51	2.02	0.12
5	S	S	W	S	S	S	W	S	S	W	S	W	S	W	S	W	S	W	S	W	0.93	0.47	0.11	0.21	5.89	0.49	0.99	1.14	0.10
6	R	S	R	R	R	S	R	R	S	R	S	R	S	R	S	R	S	R	S	R	0.45	1.13	0.15	0.45	2.26	0.74	1.39	0.69	0.12
7	R	S	R	R	R	S	R	R	S	R	S	R	S	R	S	R	S	R	S	R	0.71	0.89	0.21	0.55	2.23	0.79	1.68	0.48	0.05
8	R	S	R	R	R	S	R	R	S	R	S	R	S	R	S	R	S	R	S	R	0.68	0.73	0.18	0.65	2.69	1.02	2.16	0.64	0.05
9	R	S	R	R	R	S	R	R	S	R	S	R	S	R	S	R	S	R	S	R	0.70	0.54	0.13	0.42	2.61	0.67	1.76	0.54	0.05
10	R	S	R	R	R	S	R	R	S	R	S	R	S	R	S	R	S	R	S	R	0.53	0.96	0.27	1.11	3.42	1.35	2.85	0.93	0.08
11	S	S	R	S	S	S	R	S	S	S	R	S	S	S	R	S	S	S	R	S	0.76	0.72	0.19	0.94	2.95	1.00	2.84	0.63	0.09
12	H	Y	T	T	S	S	R	R	S	S	R	R	S	S	R	R	S	S	R	R	0.90	1.91	0.36	2.52	5.04	2.18	3.64	1.70	0.18
13	H	Y	T	T	S	S	R	R	S	S	R	R	S	S	R	R	S	S	R	R	0.74	2.22	0.59	2.87	3.84	3.11	3.96	1.92	0.33

Fab	CDR-L3					CDR-H1					CDR-H2					CDR-H3					Fraction unbound	Specificity ELISA signal Optical density (450 nm)													
	96	95	94	93	92	96	95	94	93	92	96	95	94	93	92	100a	100b	100c	100d	100e		100f	100g	100h	100i	100j	100k	100l	100m	101					
1	S	I	S	S	S	S	I	S	S	S	S	I	S	S	S	S	I	S	S	S	S	I	S	S	S	0.93	hVEGF	0.32	0.38	0.26	5.89	0.47	0.27	0.54	0.12
2	Y	I	S	S	S	S	I	S	S	S	S	I	S	S	S	S	I	S	S	S	S	I	S	S	S	0.91	hVEGF	1.45	3.77	1.08	5.89	2.06	3.61	3.65	0.52
3	Y	I	S	S	S	S	I	S	S	S	S	I	S	S	S	S	I	S	S	S	S	I	S	S	S	1.15	hVEGF	0.86	3.69	0.79	5.89	1.31	3.59	3.76	0.18
4	Y	I	S	S	S	S	I	S	S	S	S	I	S	S	S	S	I	S	S	S	S	I	S	S	S	1.00	hVEGF	0.38	0.60	0.24	5.89	0.44	0.40	1.13	0.11
5	S	I	S	S	Y	S	I	S	S	Y	S	I	S	S	Y	S	I	S	S	Y	S	I	S	S	Y	1.00	hVEGF	0.76	0.73	0.45	5.89	0.67	0.75	1.93	0.17
6	S	I	S	S	Y	S	I	S	S	Y	S	I	S	S	Y	S	I	S	S	Y	S	I	S	S	Y	0.95	hVEGF	0.06	0.00	0.04	3.54	0.11	0.01	0.29	0.03
7	S	I	S	S	Y	S	I	S	S	Y	S	I	S	S	Y	S	I	S	S	Y	S	I	S	S	Y	0.92	hVEGF	0.07	0.12	0.07	3.87	0.18	0.07	0.17	0.00
8	S	I	S	S	S	S	I	S	S	S	S	I	S	S	S	S	I	S	S	S	S	I	S	S	S	0.96	hVEGF	0.72	0.72	0.50	5.89	0.67	2.24	1.82	0.25
9	S	I	S	S	S	S	I	S	S	S	S	I	S	S	S	S	I	S	S	S	S	I	S	S	S	1.04	hVEGF	0.52	0.28	0.21	5.89	0.56	0.26	3.61	0.05
10	S	I	S	S	S	S	I	S	S	S	S	I	S	S	S	S	I	S	S	S	S	I	S	S	S	0.97	hVEGF	0.47	0.74	0.28	4.46	0.49	0.49	2.80	0.17
11	S	I	S	S	Y	S	I	S	S	Y	S	I	S	S	Y	S	I	S	S	Y	S	I	S	S	Y	1.00	hVEGF	0.04	0.01	0.08	3.74	0.14	0.05	0.14	0.00
12	S	I	S	S	S	S	I	S	S	S	S	I	S	S	S	S	I	S	S	S	S	I	S	S	S	1.06	hVEGF	0.59	0.50	0.32	5.89	0.49	0.57	1.34	0.16
13	S	I	S	S	S	S	I	S	S	S	S	I	S	S	S	S	I	S	S	S	S	I	S	S	S	1.05	hVEGF	0.33	0.73	0.32	5.89	0.36	0.93	3.80	0.05
14	S	I	S	S	S	S	I	S	S	S	S	I	S	S	S	S	I	S	S	S	S	I	S	S	S	1.02	hVEGF	0.82	0.71	0.63	3.93	0.79	3.58	2.81	0.31
15	S	I	S	S	S	S	I	S	S	S	S	I	S	S	S	S	I	S	S	S	S	I	S	S	S	1.17	hVEGF	0.94	0.67	0.57	3.79	0.81	1.24	1.99	0.29
16	S	I	S	S	S	S	I	S	S	S	S	I	S	S	S	S	I	S	S	S	S	I	S	S	S	1.01	hVEGF	0.36	0.56	0.32	5.89	0.42	0.74	1.79	0.08
17	S	I	S	S	Y	S	I	S	S	Y	S	I	S	S	Y	S	I	S	S	Y	S	I	S	S	Y	0.96	hVEGF	0.20	0.27	0.15	3.59	0.28	0.20	0.62	0.05
18	S	I	S	S	S	S	I	S	S	S	S	I	S	S	S	S	I	S	S	S	S	I	S	S	S	0.98	hVEGF	0.21	0.32	0.13	5.89	0.39	0.25	2.52	0.05
19	S	I	S	S	S	S	I	S	S	S	S	I	S	S	S	S	I	S	S	S	S	I	S	S	S	1.03	hVEGF	0.13	0.28	0.11	4.33	0.33	0.16	2.72	0.05
20	S	I	S	S	Y	S	I	S	S	Y	S	I	S	S	Y	S	I	S	S	Y	S	I	S	S	Y	1.05	hVEGF	0.58	0.59	0.25	5.89	0.28	0.25	1.65	0.08
21	S	I	S	S	S	S	I	S	S	S	S	I	S	S	S	S	I	S	S	S	S	I	S	S	S	0.97	hVEGF	0.58	0.59	0.25	3.76	0.56	0.61	1.73	0.10
22	S	I	S	S	Y	S	I	S	S	Y	S	I	S	S	Y	S	I	S	S	Y	S	I	S	S	Y	1.04	hVEGF	0.28	0.27	0.18	4.13	0.36	0.24	0.47	0.05
23	S	I	S	S	S	S	I	S	S	S	S	I	S	S	S	S	I	S	S	S	S	I	S	S	S	0.91	hVEGF	0.92	0.95	0.31	3.97	0.41	3.61	1.42	0.08
24	S	I	S	S	S	S	I	S	S	S	S	I	S	S	S	S	I	S	S	S	S	I	S	S	S	1.02	hVEGF	0.35	0.16	0.23	4.02	0.36	0.45	0.66	0.06
25	S	I	S	S	S	S	I	S	S	S	S	I	S	S	S	S	I	S	S	S	S	I	S	S	S	1.15	hVEGF	0.28	0.60	0.24	4.08	0.37	2.11	3.61	0.09
26	Y	I	S	S	Y	S	I	S	S	Y	S	I	S	S	Y	S	I	S	S	Y	S	I	S	S	Y	0.99	hVEGF	0.72	0.27	0.34	3.60	0.57	0.42	0.85	0.13
27	S	I	S	S	Y	S	I	S	S	Y	S	I	S	S	Y	S	I	S	S	Y	S	I	S	S	Y	1.10	hVEGF	0.69	0.42	0.28	5.89	0.52	0.36	1.25	0.12
28	S	I	S	S	Y	S	I	S	S	Y	S	I	S	S	Y	S	I	S	S	Y	S	I	S	S	Y	1.00	hVEGF	0.68	0.37	0.30	3.78	0.57	0.40	0.86	0.10
29	S	I	S	S	Y	S	I	S	S	Y	S	I	S	S	Y	S	I	S	S	Y	S	I	S	S	Y	0.95	hVEGF	0.62	0.46	0.33	5.89	0.62	0.55	0.94	0.12
30	S	I	S	S	S	S	I	S	S	S	S	I	S	S	S	S	I	S	S	S	S	I	S	S	S	0.85	hVEGF	0.55	0.56	0.32	5.89	0.56	0.68	1.01	0.13
31	S	I	S	S	S	S	I	S	S	S	S	I	S	S	S	S	I	S	S	S	S	I	S	S	S	0.95	hVEGF	0.23	0.21	0.15	5.89	0.42	0.15	3.78	0.05
32	S	I	S	S	S	S	I	S	S	S	S	I	S	S	S	S	I	S	S	S	S	I	S	S	S	0.99	hVEGF	0.43	0.27	0.26	3.40	0.49	0.17	5.87	0.02
33	S	I	S	S	S	S	I	S	S	S	S	I	S	S	S	S	I	S	S	S	S	I	S	S	S	1.06	hVEGF	0.29	0.72	0.23	5.89	0.42	0.34	0.93	0.05
34	S	I	S	S	S	S	I	S	S	S	S	I	S	S	S	S	I	S	S	S	S	I	S	S	S	0.88	hVEGF	0.18	0.39	0.15	4.13	0.42	0.13	1.37	0.07
35	Y	I	S	S	S	S	I	S	S	S	S	I	S	S	S	S	I	S	S	S	S	I	S	S	S	1.08	hVEGF	0.51	0.61	0.36	3.61	0.65	0.55	2.41	0.11
36	S	I	S	S	S	S	I	S	S	S	S	I	S	S	S	S	I	S	S	S	S	I	S	S	S	0.93	hVEGF	0.39	0.22	0.24	3.63	0.63	0.23	0.63	0.04
37	S	I	S	S	Y	S	I	S	S	Y	S	I	S	S	Y	S	I	S	S	Y	S	I	S	S	Y	1.00	hVEGF	1.20	0.98	0.63	4.64	0.95	0.91	3.52	0.30
38	S	I	S	S	S	S	I	S	S	S	S	I	S	S	S	S	I	S	S	S	S	I	S	S	S	0.95	hVEGF	0.40	0.30	0.24	5.89	0.63	0.25	0.69	0.13
39	S	I	S	S	S	S	I	S	S	S	S	I	S	S	S	S	I	S	S	S	S	I	S	S	S	0.92	hVEGF	0.31	0.36	0.22	4.10	0.78	0.32	0.42	0.06
40	S	I	S	S	S	S	I	S	S	S	S	I	S	S	S	S	I	S	S	S	S	I	S	S	S	0.95	hVEGF	0.31	0.21	1.09	5.89	0.56	0.21	0.49	0.01
41	S	I	S	S	Y	S	I	S	S	Y	S	I	S	S	Y	S	I	S	S	Y	S	I	S	S	Y	0.79	hVEGF	0.21	0.28	0.17	3.46	0.81	0.14	0.58	0.05
42	S	I	S	S	S	S	I	S	S	S	S	I	S	S	S	S	I	S	S	S	S	I	S	S	S	1.07	hVEGF	-0.06	0.12	-0.02	5.89	0.20	0.04	0.11	0.03
43	S	I	S	S	S	S	I	S	S	S	S	I	S	S	S	S	I	S	S	S	S	I	S	S	S	1.03	hVEGF	0.38	0.39	0.20	5.89	0.45	0.36	0.93	0.08
44	S	I	S	S	S	S	I	S	S	S	S	I	S	S	S	S	I	S	S	S	S	I	S	S	S	1.00	hVEGF	0.43	0.67	0.31	3.65	0.88	0.45	1.11	0.05
45	Y	I	S	S	S	S	I	S	S	S	S	I	S	S	S	S	I	S	S	S	S	I	S	S	S	0.87	hVEGF	0.24	0.12	0.14	0.29	0.57	0.18	0.67	0.05

Supplemental Figure S3c

Fab	CDR-L3	CDR-H1	CDR-H2	CDR-H3	Fraction unbound	Specificity ELISA signal Optical density (450 nm)						
						HER2	hInsulin	NAV	HGH	hIGF-1	BSA	
98					0.76	5.88	0.08	0.05	0.01	-0.03	0.00	0.10
99					0.93	3.62	-0.06	0.01	0.02	0.00	-0.03	-0.06
100					1.03	4.33	-0.10	0.06	-0.03	0.06	0.02	0.00
101					1.04	3.58	-0.10	0.03	-0.01	0.08	-0.06	0.05
102					1.01	5.88	-0.09	-0.03	0.01	0.07	-0.06	-0.06
103					0.96	3.76	-0.13	-0.01	-0.02	0.01	-0.06	-0.05
104					0.99	3.36	-0.02	0.00	0.05	-0.01	0.01	-0.05
105					0.93	3.86	-0.03	-0.02	0.03	0.06	-0.03	0.01
106					1.05	3.88	-0.01	-0.02	0.05	0.05	-0.03	0.04
107					0.94	3.67	-0.02	0.08	0.00	0.13	0.01	0.02
108					1.03	N/D	N/D	N/D	N/D	N/D	N/D	N/D
109					0.93	4.18	-0.08	0.11	0.03	0.05	-0.06	-0.04
110					0.94	3.58	-0.08	0.00	0.03	0.10	-0.04	-0.05
111					0.90	5.88	-0.03	0.00	0.02	0.00	-0.04	-0.05
112					0.76	5.88	-0.12	-0.02	-0.03	0.06	-0.05	-0.02
113					0.92	3.67	-0.11	-0.02	0.11	-0.02	-0.05	0.08
114					0.89	3.37	-0.10	-0.01	0.01	0.03	0.00	-0.03
115					0.96	4.15	0.03	0.01	0.12	0.02	0.02	-0.05
116					0.90	4.58	-0.10	0.04	0.02	0.03	-0.03	-0.01
117					1.01	4.03	-0.03	0.01	0.00	-0.03	-0.03	0.04
118					1.04	4.03	-0.03	0.01	0.00	-0.03	-0.03	0.04
119					0.97	5.88	-0.01	0.06	0.00	0.00	-0.01	0.00
120					0.89	5.88	0.07	0.15	0.11	-0.01	-0.04	-0.04
121					0.86	5.88	-0.01	0.05	0.07	-0.01	-0.04	-0.04
122					0.99	3.44	-0.05	0.04	-0.03	0.10	0.04	-0.01
123					0.94	N/D	N/D	N/D	N/D	N/D	N/D	N/D
124					0.88	5.88	-0.07	0.07	0.02	0.00	-0.04	-0.03
125					0.90	3.58	-0.02	0.00	-0.02	0.02	-0.04	-0.04
126					0.88	3.39	-0.10	-0.01	0.00	0.07	0.04	-0.05
127					0.96	3.90	0.06	0.05	0.05	0.06	0.01	0.00
128					0.96	3.69	-0.03	0.03	0.13	0.01	-0.03	0.00
129					0.91	4.86	0.01	-0.01	0.11	-0.01	-0.02	-0.02
130					1.04	4.46	-0.06	0.03	0.09	0.04	0.09	-0.01
131					1.04	3.42	-0.03	0.09	0.04	0.09	-0.01	0.03
132					1.02	5.88	-0.06	0.03	0.03	0.10	0.03	-0.01
133					0.95	N/D	N/D	N/D	N/D	N/D	N/D	N/D
134					0.97	N/D	N/D	N/D	N/D	N/D	N/D	N/D
135					0.90	3.49	-0.01	0.02	0.06	0.01	-0.03	-0.03
136					1.00	3.38	-0.04	-0.03	0.03	0.00	0.00	-0.03
137					1.00	3.98	0.08	0.03	0.04	0.06	0.06	0.00
138					0.96	3.42	-0.08	0.02	0.01	0.01	-0.04	-0.05
139					0.95	3.46	-0.03	0.08	0.04	0.06	-0.04	-0.02
140					0.90	3.81	-0.08	0.04	-0.01	0.02	0.05	-0.04
141					0.98	4.08	-0.05	0.02	0.02	0.01	-0.02	-0.04
142					0.98	4.08	-0.05	0.02	0.02	0.01	-0.02	-0.04
143					1.00	3.56	-0.05	0.04	0.04	0.04	-0.04	0.03
144					1.09	3.56	-0.05	0.04	0.04	0.04	-0.04	0.03
145					0.93	4.46	-0.01	0.04	-0.01	0.08	-0.04	-0.03
146					0.95	N/D	N/D	N/D	N/D	N/D	N/D	N/D
147					0.99	3.74	0.07	0.03	0.04	0.03	0.04	-0.01
148					0.99	3.50	-0.01	0.17	0.00	0.05	-0.05	0.04
149					1.05	5.88	0.07	0.14	0.03	0.11	0.04	0.00
150					0.83	5.88	0.09	0.16	0.19	0.02	0.03	0.12
151					0.98	4.58	-0.09	0.14	0.03	0.06	-0.02	0.11
152					0.85	3.43	-0.01	0.01	0.01	0.05	-0.02	0.04
153					0.96	3.44	-0.05	0.03	0.02	0.05	0.03	0.05
154					1.02	5.55	-0.07	0.05	-0.02	0.03	-0.02	-0.03
155					1.02	5.55	-0.07	0.05	-0.02	0.03	-0.02	-0.03
156					0.99	N/D	N/D	N/D	N/D	N/D	N/D	N/D
157					1.14	3.59	0.08	0.04	0.07	0.03	0.01	0.09
158					0.98	5.88	0.03	0.03	0.06	0.05	-0.02	0.01
159					0.99	N/D	N/D	N/D	N/D	N/D	N/D	N/D
160					0.96	5.88	-0.05	0.00	0.02	0.00	-0.04	-0.06
161					1.00	-0.06	-0.02	0.11	-0.01	0.08	0.02	0.04
162					0.91	3.22	-0.06	0.00	0.02	0.03	-0.04	0.01
163					0.92	3.70	0.01	0.09	0.07	0.04	0.03	0.02
164					0.95	3.35	-0.10	0.04	0.05	0.04	0.02	-0.05
165					0.98	5.88	0.14	0.13	0.08	0.16	0.05	0.43
166					0.92	5.88	0.14	0.13	0.08	0.16	0.05	0.43
167					0.90	3.63	0.15	0.10	0.24	-0.04	-0.02	0.07
168					0.92	5.56	-0.09	0.17	-0.03	0.14	-0.02	0.42
169					0.68	5.56	-0.09	0.17	-0.03	0.14	-0.02	0.42
170					0.51	3.57	-0.08	0.00	0.06	0.02	0.02	-0.04

Supplemental Figure S3d

Fab	CDR-L3				CDR-H1				CDR-H2				CDR-H3				Fraction unbound	Specificity ELISA signal Optical density (450 nm)																		
	16	92	94	96	28	29	30	31	32	33	50	51	52	53	54	55		56	57	58	98	99	100	100a	100b	100c	100d	100e	100f	100g	100h	100i	100j	101		
171	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	0.39	5.75	0.08	0.10	0.12	0.07	0.09	0.03
172	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	0.39	5.75	0.08	0.12	0.11	0.08	0.19	0.03
173	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	0.37	5.42	0.06	0.07	0.11	0.04	0.09	0.04
174	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	0.16	5.75	0.07	0.09	0.12	0.08	0.15	0.04
175	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	0.21	3.63	0.13	0.15	0.22	0.15	0.29	0.05
176	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	0.06	5.75	0.09	0.09	0.09	0.05	0.19	0.00
177	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	0.25	5.75	0.09	0.08	0.12	0.05	0.22	-0.01
178	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	0.31	3.99	0.05	0.06	0.07	0.07	-0.03	
179	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	0.37	3.56	0.03	0.08	0.14	0.07	0.10	-0.01
180	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	0.38	5.75	0.07	0.14	0.27	0.12	0.20	0.00
181	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	0.08	5.75	0.06	0.05	0.17	0.10	0.18	0.02
182	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	0.41	3.93	0.12	0.08	0.13	0.08	0.13	0.10
183	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	0.42	3.50	0.10	0.10	0.25	0.11	0.21	0.06
184	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	0.50	3.54	0.06	0.09	0.16	0.05	0.07	0.03
185	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	0.82	3.68	0.06	0.05	0.13	0.03	0.07	-0.04
186	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	0.14	3.93	0.10	0.20	0.15	0.14	0.28	0.04
187	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	0.23	5.75	0.13	0.20	0.23	0.09	0.23	0.02
188	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	0.16	4.16	0.10	0.13	0.16	0.04	0.13	0.01
189	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	0.23	5.75	0.05	0.09	0.13	0.04	0.14	0.00
190	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	0.20	5.75	0.14	0.09	0.13	0.10	0.18	0.01
191	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	0.25	5.75	0.05	0.10	0.10	0.10	0.18	0.01
192	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	0.26	4.38	0.16	0.16	0.18	0.10	0.19	0.10
193	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	0.27	3.54	0.05	0.10	0.14	0.08	0.09	0.00
194	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	0.06	3.68	0.08	0.03	0.18	0.11	0.07	0.06
195	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	0.30	5.75	0.05	0.10	0.13	0.10	0.11	0.04
196	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	0.04	5.75	0.09	0.10	0.09	0.06	0.08	0.06
197	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	0.08	3.85	0.10	0.14	0.07	0.04	0.13	-0.02
198	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	0.05	3.95	0.04	0.09	0.06	0.04	0.08	0.01
199	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	0.34	5.75	0.16	0.12	0.15	0.22	0.17	0.05
200	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	0.06	4.83	0.09	0.13	0.10	0.05	0.11	-0.02
201	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	0.14	4.44	0.11	0.14	0.17	0.09	0.22	0.03
202	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	0.06	5.75	0.08	0.09	0.13	0.04	0.12	-0.02
203	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	0.18	5.75	0.08	0.15	0.13	0.05	0.20	0.00
204	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	0.09	5.75	0.05	0.03	0.08	0.03	0.04	0.04
205	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	0.08	3.72	0.09	0.10	0.15	0.08	0.14	0.04
206	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	0.10	3.58	0.12	0.17	0.12	0.06	0.18	0.04
207	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	0.41	3.79	0.12	0.09	0.14	0.08	0.12	0.04
208	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	0.12	3.75	0.13	0.13	0.14	0.07	0.12	0.00
209	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	0.21	5.75	0.12	0.21	0.23	0.13	0.20	0.03
210	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	0.13	5.75	0.10	0.12	0.13	0.08	0.12	0.10
211	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	0.47	3.53	0.09	0.10	0.08	0.08	0.12	0.02
212	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	0.55	3.85	0.07	0.19	0.05	0.01	0.15	-0.02
213	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	0.46	5.75	0.11	0.13	0.27	0.11	0.18	0.00
214	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	0.05	4.02	0.07	0.10	0.11	0.05	0.12	0.02
215	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	0.10	3.36	0.11	0.18	0.22	0.11	0.27	0.05
216	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	0.09	3.72	0.09	0.25	0.15	0.09	0.24	0.05
217	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	0.81	5.75	0.13	0.18	0.15	0.23	0.24	0.02
218	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	0.09	3.62	0.13	0.16	0.14	0.06	0.28	0.04
219	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	0.06	5.75	0.11	0.17	0.14	0.08	0.17	0.02

